1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )TABLE 3:Comparison of T1 metrics between control participants and patients with multiple sclerosis
White Matter Gray Matter Relative Height Relative Distance Position Width Position Width Control participants 667 70 1077 233 2.26 409 All patients with MS 722 83 1090 207 2.05 367 P values <0.001 <0.001 0.33 <0.001 0.003 <0.001 RRMS and SPMS 714 79 1088 212 2.02 373 P values <0.001 0.001 0.38 0.002 0.002 <0.001
Note.—The two-tailed Student’s t test with unequal variance is used to derive statistical significances (P values). MS, multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis.